Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit
AUSTIN, Texas, May 13, 2021 (GLOBE NEWSWIRE) Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will be presenting at the Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 and will be hosting virtual one-on-one meetings with investors throughout the day.
Live Presentation 10:45 AM – 11:25 AM (ET)
The live Lumos Pharma presentation can be accessed through the link Oppenheimer Rare & Orphan Disease Summit (wsw.com). The link can also be found on the Company’s website under “Events & Presentations” in the Investors & Media section where a replay will be available for 90 days. Please contact your Oppenheimer salesperson or Lumos Pharma Investor Relations to schedule one-on-one meetings with the management team during the Summit or thereafter.
Chemomab to Present at Oppenheimer s Virtual Rare and Orphan Disease Summit
USA - English
Share this article
Share this article
TEL AVIV, Israel, May 12, 2021 /PRNewswire/ Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced that the company s CEO, Dr. Adi Mor will present a corporate update at Oppenheimer s virtual Rare and Orphan Disease Summit on May 21
st, 2021.
Webcast link may be accessed here.
The presentation will be available for 30 days following the event on the Company s investors section at the Chemomab website.